Recombinant factor VIIa. An update on its clinical use.
Recombinant activated factor VII (rFVIIa, NovoSeven) has been successfully used to treat bleeding episodes in patients with antibodies against coagulation factors VIII and IX. In recent years, rFVIIa has also been employed for the management of uncontrolled bleeding in a number of congenital and acquired haemostatic abnormalities. Based on a literature search, this review examines the current knowledge on therapy with rFVIIa, from the now well-standardized uses to the newer and less well-characterised clinical applications.
Franchini
Massimo
M
Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Ospedale Policlinico, Piazzale Ludovico Scuro, 37134 Verona, Italy. massimo.franchini@mail.azosp.vr.it
Zaffanello
Marco
M
Veneri
Dino
D
D001778:Blood Coagulation Disorders / Q000188:drug therapy; D001791:Blood Platelet Disorders / Q000188:drug therapy; D015942:Factor VIIa / Q000502:physiology / Q000627:therapeutic use*; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D006474:Hemorrhagic Disorders / Q000188:drug therapy; D006488:Hemostasis, Surgical; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy; D011994:Recombinant Proteins / Q000627:therapeutic use; D014947:Wounds and Injuries / Q000188:drug therapy
D011994:Recombinant Proteins; D015942:Factor VIIa